REJUVXL
LIVE

Serial Number

98189228

Owner

AION Healthspan, Inc.

Attorney

Michael R. Graif

Filing Date

Sep 20, 2023

Add to watchlist:

No watchlists yet
View on USPTO

REJUVXL Trademark

Serial Number: 98189228

REJUVXL is a trademark filed by AION Healthspan, Inc. on September 20, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

AION Healthspan, Inc. (5 trademarks)

550 Bay Point Road
Miami, FL 33137

Entity Type: 03

Trademark Details

Filing Date

September 20, 2023

Registration Date

Not Registered

Published for Opposition

July 1, 2025

Goods & Services

Medical and scientific research and development in the field of cell therapy, regenerative medicine and healthspan medicine; cell therapy preparation in the nature of testing for research, development, engineering and testing services in the fields of immunopharmaceuticals, immunomodulators

Cell therapy preparation in the nature of cells for development use, other than for medical or veterinary purposes

Cell therapy preparation in the nature of cells for medical and clinical use; cell therapy preparation in the nature of cryopreserved cells for medical and clinical use; cell therapy preparation in the nature of cell suspension being living cells for medical and clinical use; cell therapy preparation in the nature of pharmaceutical preparations, namely, living cells for injection for medical and clinical use for treating chronic, inflammatory, or immune-mediated conditions; cell therapy preparation in the nature of pharmaceutical preparations, namely, living cells, for infusion for medical and clinical use for treating kidney disease; cell therapy preparation in the nature of pharmaceutical preparations, namely, living cells for treating chronic diseases such as chronic kidney disease, inflammatory diseases such as lung disease, immune-mediated conditions such as autoimmune disease or graft-versus-host disease, degenerative diseases such as neurodegenerative diseases; cell therapy preparation in the nature of cell clusters being living cells clusters for medical and clinical use; cell therapy preparation in the nature of tissue being biological tissue cultures for medical and clinical use; therapeutic preparation in the nature of cell derivatives being biological materials derived from cells, namely extracellular vesicles, secretome, conditioned media, soluble factors, membrane fragments, or extracellular matrix for medical and clinical use; cell therapy preparation in the nature of pharmaceutical preparations comprised of molecules for combination with cell therapy for medical and clinical use for treating kidney disease; cell therapy preparation in the nature of pharmaceutical preparations comprised of molecules for combination with cells for medical and clinical use for treating chronic, inflammatory, or immune-mediated conditions; cell therapy preparation in the nature of pharmaceutical preparations comprised of supramolecular complexes in combination with cells for medical and clinical use for treating chronic, inflammatory, or immune-mediated conditions; cell therapy preparation of cell components being mitochondria or vesicles for medical and clinical use

Medical services; medical treatment using cultured cells; medical treatment of Chronic Kidney Disease using living cells; medical treatment, namely, injection of living cells for the treatment of chronic, inflammatory, or immune-mediated conditions; medical treatment, namely, infusion of living cells for the treatment of chronic, inflammatory, or immune-mediated conditions; medical treatment, namely, injection, infusion, and implantation of living cells in combination with induction and maintenance treatment with vitamins, protective molecules, and pharmacological agents for the treatment of Chronic Kidney Disease

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 24, 2026 EXRA
SOU EXTENSION 1 GRANTED
Feb 23, 2026 EX1G
SOU EXTENSION 1 FILED
Feb 23, 2026 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 23, 2026 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 26, 2025 NOAM
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jul 31, 2025 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 31, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 31, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 31, 2025 REAP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 1, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jul 1, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 25, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 29, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 28, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 28, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
May 28, 2025 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 26, 2025 GNFN
FINAL REFUSAL E-MAILED
Mar 26, 2025 GNFR
FINAL REFUSAL WRITTEN
Mar 26, 2025 CNFR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 10, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 10, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 10, 2025 REAP
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 4, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 4, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 4, 2025 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Nov 27, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Nov 27, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 4, 2024 GNRN
NON-FINAL ACTION E-MAILED
Sep 4, 2024 GNRT
NON-FINAL ACTION WRITTEN
Sep 4, 2024 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 14, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 14, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 14, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 9, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jul 9, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jul 9, 2024 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Jul 9, 2024 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Jun 18, 2024 PBCR
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 4, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 31, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 31, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 31, 2024 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 16, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 16, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 16, 2024 REAP
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 14, 2024 GNRN
NON-FINAL ACTION E-MAILED
May 14, 2024 GNRT
NON-FINAL ACTION WRITTEN
May 14, 2024 CNRT
ASSIGNED TO EXAMINER
May 14, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 6, 2023 NWOS
NEW APPLICATION ENTERED
Sep 23, 2023 NWAP